Benzinga | Apr 13, 2021 06:59AM EDT

BD MAX Molecular Multi-Drug Resistant Tuberculosis Test To Be Included In WHO Updated Consolidated Guidelines On Tuberculosis

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that its BD MAX(tm) Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was included in the moderate complexity automated NAAT class of molecular diagnostic technologies that were recognized for high diagnostic accuracy for tuberculosis testing by the World Health Organization (WHO) in advance of an update to its guidelines for TB diagnostic tests.